BioSpace News Archive

Statera Biopharma, Inc. today announced that Michael K. Handley, President and Chief Executive Officer, has been invited to participate as an expert speaker during the 2nd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit.

Harpoon Therapeutics, Inc. today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in China evaluating AMZEEQ® (minocycline) topical foam, 4% in moderate to severe acne.

Outlook Therapeutics, Inc. today announced that C. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, will make a company presentation at the OIS Retina Innovation Showcase

Extendicare Inc. announced that it plans to release its financial results for the third quarter of 2021 after market close on Thursday, November 4, 2021.

VBL Therapeutics (Nasdaq: VBLT ) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective immediately.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that the Israeli Patent Office issued a notice of allowance for a new patent application (number 255119) covering AllocetraTM, the Company’s immunotherapy product candidate.

Akero Therapeutics, Inc. today announced that Tim Rolph, Akero’s Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 12:00 p.m. (ET).

- UDENYCA ® On-Body Injector (OBI) Achieved Both Pharmacokinetic and Pharmacodynamic Bioequivalence in Randomized Clinical Trial

Centessa Pharmaceuticals plc today announced that David Grainger, PhD, has been appointed to the newly-created role of Chief Innovation Officer.